Although radiation carcinogenesis has been shown both experimentally and
epidemiologically, the use of ionizing radiation is also one of the major modalities in cancer …

Targeted cancer therapies exploit the continued dependence of cancer cells on oncogenic
mutations. Such agents can have remarkable activity against some cancers, although …

Hemizygous deletion of 17p13, which harbors the TP53 gene, has been identified in> 10%
of newly diagnosed multiple myeloma (MM) patients and is associated with poor prognosis …

The emergence of resistance to imatinib mediated by mutations in the BCR-ABL has
become a major challenge in the treatment of chronic myeloid leukemia (CML). Alternative …

AIMS: To identify whether phosphatidylinositol 3-kinase/Akt and mitogen-activated protein
kinase/extracellular-regulated protein kinases signalling pathways are implicated in the …

Recent findings showed that BRCA1, in addition to its role in DNA damage response, acts
as an upstream regulator of genes involved in the mitotic checkpoint regulation, thus …

The genetic or functional inactivation of the p53 pathway plays an important role with
regards to disease progression from the chronic phase (CP) to blast phase (BP) and imatinib …

药物诱导的长散在重复序列LINE-1 异常激活可促进细胞基因组不稳定, 而基因组不稳定是促进
肿瘤发生发展和耐药表型形成的重要因素. 因此, 探索LINE-1 异常激活的分子机制具有重要的 …

Background: p53 alterations have been implicated in the development of many cancers,
such as gastric cancer, but there is no evidence of p53 intron alterations in gastritis lesions …

The chronic phase (CP) of chronic myeloid leukemia (CML) is characterized by the
expression of chimeric BCR/ABL gene, extended survival, and profligate growth of maturing …